Ashish Kamat, MD, MBBS, FACS

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    BioClin Therapeutics
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Roviant
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Photocure
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Merck
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    FerGene
    Mitigation strategy: 
    Divest
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Astra Zeneca
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Heat Biologics
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (General Urology)
    Ineligible company: 
    Adolor
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Leadership Position (Specialty Not Specified)
    Ineligible company: 
    IBCG
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Specialty Not Specified)
    Ineligible company: 
    FKD
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023

Pages

Return to The Journal of Urology Vol. 210 (2023): November